Paid Prostate Cancer Clinical Trials
Prostate cancer clinical trials now enrolling. Access new hormone therapies and immunotherapies. Compensation available for metastatic and localized prostate cancer.
Compensation
$1,500 - $4,000
Duration
24-104 weeks
Phase
Phase II/III
FDA Regulated
IRB Approved
GCP Certified
Who May Qualify
- Age 18 years or older
- Histologically confirmed prostate adenocarcinoma
- Disease stage appropriate for specific study (localized, biochemical recurrence, or metastatic)
- ECOG performance status 0-1
- Adequate organ function
- Willing to continue androgen deprivation therapy if applicable
Who May Not Qualify
- Small cell or neuroendocrine prostate cancer
- Prior treatment with specific agents (study-dependent)
- Symptomatic brain metastases
- Other malignancy within 5 years (exceptions apply)
- Uncontrolled cardiovascular disease
Frequently Asked Questions
What prostate cancer treatments are being studied?
+
Trials are investigating new androgen receptor inhibitors, PARP inhibitors for specific mutations, radiopharmaceuticals, immunotherapies, and combination approaches for various disease stages.
Do I need specific genetic testing?
+
Some studies require tumor or germline genetic testing to determine eligibility (BRCA, HRR mutations). This testing is often provided as part of screening.
What monitoring is required during the study?
+
Regular PSA testing, imaging scans, and blood tests monitor disease status and safety. Visit frequency varies but is typically every 4-12 weeks.
Can I participate if my cancer has spread?
+
Yes, many studies specifically enroll patients with metastatic castration-resistant prostate cancer (mCRPC). Studies also exist for earlier disease stages.